PDS Biotechnology Corp
PDSB0.715USD
+0.025+3.59%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
34.11MValor de mercado
PerdaP/L TTM
Mais detalhes de PDS Biotechnology Corp Empresa
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Informações de PDS Biotechnology Corp
Código da empresaPDSB
Nome da EmpresaPDS Biotechnology Corp
Data de listagemOct 01, 2015
CEOBedu-Addo (Frank)
Número de funcionários24
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 01
Endereço303A College Road East
CidadePRINCETON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08540
Telefone18002083343
Sitehttps://www.pdsbiotech.com
Código da empresaPDSB
Data de listagemOct 01, 2015
CEOBedu-Addo (Frank)
Executivos da empresa PDS Biotechnology Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Lars Boesgaard
Mr. Lars Boesgaard
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
3.73%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
Outro
92.22%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
3.73%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
Outro
92.22%
Tipos de investidores
Investidores
Proporção
Investment Advisor
6.56%
Individual Investor
2.69%
Investment Advisor/Hedge Fund
2.12%
Hedge Fund
1.29%
Research Firm
0.65%
Venture Capital
0.04%
Outro
86.65%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
172
5.60M
10.70%
-4.10M
2025Q3
178
7.65M
16.41%
-3.65M
2025Q2
188
9.63M
21.07%
+1.19M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
1.90M
3.63%
-49.90K
-2.56%
Sep 30, 2025
Bedu-Addo (Frank)
690.87K
1.32%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
508.21K
0.97%
+3.13K
+0.62%
Sep 30, 2025
Geode Capital Management, L.L.C.
482.00K
0.92%
+64.06K
+15.33%
Sep 30, 2025
Sykes (Richard)
445.11K
0.85%
--
--
Apr 17, 2025
Citadel Advisors LLC
386.43K
0.74%
+137.41K
+55.18%
Sep 30, 2025
Squarepoint Capital LLP
291.63K
0.56%
+193.86K
+198.29%
Sep 30, 2025
Renaissance Technologies LLC
275.86K
0.53%
+170.17K
+161.02%
Sep 30, 2025
UBS Financial Services, Inc.
86.26K
0.16%
-337.96K
-79.67%
Sep 30, 2025
William Blair & Company, L.L.C. (Research)
250.00K
0.48%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares UltraPro Russell2000
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
